Elacestrant dihydrochloride NEW
| Price | $122 | $249 | $396 |
| Package | 1mg | 5mg | 10mg |
| Supply Ability: | 10g |
| Update Time: | 2026-06-05 |
Product Details
| Product Name: Elacestrant dihydrochloride | CAS No.: 1349723-93-8 |
| Purity: 99.98% | Supply Ability: 10g |
| Release date: 2026/06/05 |
Product Introduction
Bioactivity
| Name | Elacestrant dihydrochloride |
| Description | Elacestrant dihydrochloride (DA-DKRAD1901 dihydrochloride) is an orally available selective estrogen receptor degrader with IC50s of 48 for ERα and 870 nM for ERβ, respectively. |
| In vitro | Elacestrant exhibits inhibition of ERα expression in a dose-dependent manner, with an EC50 of 0.6 nM.?Treatment of ER-positive MCF-7 cells with E2 results in a potent and dose-dependent increase in proliferation, with an EC50 of 4 pM.?Treatment of cells with Elacestrant in the presence of 10 pM E2 results in a dose-dependent decrease in proliferation, with an IC50 value of 4.2 nM. Elacestrant selectively binds to and degrades the ER and is a potent antagonist of ER-positive breast cancer cell proliferation[1].? |
| In vivo | In MCF-7 xenograft models, Elacestrant-treated animals survived longer than those treated with either control or ICI 182780. RAD1901 preserves ovariectomy-induced bone loss and prevents the uterotropic effects of E2. Elacestrant produces a robust and profound inhibition of tumor growth in MCF-7 xenograft models[1].? |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+90% Saline : 7.21 mg/mL (13.56 mM), Solution. DMSO : 72.14 mg/mL (135.71 mM), Sonication is recommended. 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (3.76 mM), Sonication is recommended. H2O : 40 mg/mL (75.25 mM), Sonication is recommended. |
| Keywords | RAD-1901 Dihydrochloride | RAD1901 Dihydrochloride | RAD-1901 | RAD1901 | RAD 1901 Dihydrochloride | RAD 1901 | progestogenReceptor | progestogen Receptor | Inhibitor | inhibit | EstrogenReceptor | Estrogen Receptor/ERR | Estrogen Receptor | ERβ | ERα | Elacestrant Dihydrochloride | Elacestrant |
| Inhibitors Related | Tamoxifen | Mifepristone | Estradiol | Astragaloside IV | Bisphenol B | Bisphenol Z | Mequinol | Phthalic acid | Ethisterone | Alpha-Estradiol | Ferrous Bisglycinate | Cholesterol |
| Related Compound Libraries | Bioactive Compound Library | Approved Drug Library | Anti-Breast Cancer Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Endocrinology-Hormone Compound Library | Anti-Cancer Approved Drug Library | Orally Active Compound Library | Clinical Compound Library | Bioactive Compounds Library Max | Anti-Cancer Active Compound Library | Anti-Cancer Drug Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
|
VIP3Y
|
BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD.
|
2026-06-30 | ||
| $122.00 |
VIP6Y
|
TargetMol Chemicals Inc.
|
2026-06-05 | |
|
VIP1Y
|
Guangzhou Weiaokang Pharmaceutical Technology Co., Ltd
|
2025-08-27 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, USA
INQUIRY